Anzeige
Mehr »
Login
Mittwoch, 15.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Löst diese riesige Entdeckung die Kupferkrise der KI? So ändert sich die Rechnung durch diesen Explorer!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40P16 | ISIN: SE0022419784 | Ticker-Symbol: 61L0
Frankfurt
15.01.25
08:09 Uhr
21,400 Euro
-0,340
-1,56 %
1-Jahres-Chart
SECTRA AB Chart 1 Jahr
5-Tage-Chart
SECTRA AB 5-Tage-Chart
RealtimeGeldBriefZeit
21,94022,38016:41
PR Newswire
298 Leser
Artikel bewerten:
(1)

Norwegian healthcare region expands enterprise imaging contract with Sectra--digitizes pathology diagnostics to improve cancer care

Finanznachrichten News

LINKÖPING, Sweden, Dec. 9, 2024 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) announces that the Norwegian healthcare region Helse Nord RHF will expand its usage of Sectra's enterprise imaging solution to include digital pathology. The digital workflow will make it easier for pathologists to review and collaborate around cases, ultimately enhancing patient care, particularly within cancer.

"We have used Sectra's solution for many years to enhance our radiology operations and now look forward to realizing similar benefits in the diagnostic workflows in pathology. We anticipate that the digital solution will enhance collaboration both between hospitals who often support each other with second opinions and expertise, and between the medical specialties that collaborate in complex care pathways such a cancer care," says Kai-Sverre Fjellberg, Imaging Services Manager at Helse Nord RHF.

Digital pathology leads to numerous advantages for hospitals, pathologists, and patients. Sectra's digital pathology solution will provide Helse Nord RHF with a vendor-neutral and scalable solution that will help minimize time spent on manual processes and strengthen data security. The pathologists will complement their use of microscopes with the digital solution, allowing them to review and collaborate around cases in a way that has not been possible before. They will now have instant and, if needed, remote access to digital images of tissue samples instead of relying on physical glass slides reviewed in microscopes.

The pathology contract was signed in November 2024 and is an extension of their use of Sectra's solutions. They have used Sectra's solutions since 2011.

"We are thrilled to expand our partnership with Helse Nord RHF to include digital pathology. Many healthcare providers are adopting an enterprise imaging strategy as a key component to enhance patient outcomes. By integrating digital pathology into their workflow, Helse Nord RHF will experience enhanced collaboration among pathologists and other medical specialties, leading to more accurate and timely diagnoses," says Petter Østbye, General Manager, Sectra Scandinavia.

The digital pathology module is part of Sectra's enterprise imaging solution that provides a unified strategy for all imaging needs while lowering operational costs. The scalable and modular solution, with a VNA at its core, allows healthcare providers to grow from ology to ology and from enterprise to enterprise. Visit Sectra's website to read more about Sectra and why it's top-ranked in "Best in KLAS".

About Sectra

Sectra contributes to a healthier and safer society by assisting health systems throughout the world to enhance the efficiency of care, and authorities and defense forces in Europe to protect society's most sensitive information. The company, founded in 1978, is headquartered in Linköping, Sweden, with direct sales in 19 countries, and distribution partners worldwide. Sales in the 2023/2024 fiscal year totaled SEK 2,964 million. The Sectra share is quoted on the Nasdaq Stockholm exchange. For more information, visit Sectra's website.

For further information, please contact:
Dr. Torbjörn Kronander, CEO and President Sectra AB, 46 (0) 705 23 52 27
Marie Ekström Trägårdh, Executive Vice President Sectra AB and President Sectra Imaging IT Solutions, 46 (0)708 23 56 10

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/sectra/r/norwegian-healthcare-region-expands-enterprise-imaging-contract-with-sectra-digitizes-pathology-diag,c4076746

The following files are available for download:

https://news.cision.com/sectra/i/sectra-s-digital-pathology-module,c3358567

Sectra's digital pathology module

Cision View original content:https://www.prnewswire.co.uk/news-releases/norwegian-healthcare-region-expands-enterprise-imaging-contract-with-sectradigitizes-pathology-diagnostics-to-improve-cancer-care-302325950.html

© 2024 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.